New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
11:55 EDTCELG, CELG, THLD, THLD, NLNK, NLNKCowen's biotech analyst research team holds an analyst/industry conference call
Biotech Analyst Research Team provides an update on pancreatic cancer with a focus on Celgene, Threshold Pharmaceuticals and NewLink Genetics on an Analyst/Industry conference call to be held on January 29 at 12 pm.
News For CELG;THLD;NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
10:59 EDTCELGCelgene call activity attributed to vague takeover speculation
Subscribe for More Information
10:22 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
10:22 EDTCELGRumor: Celgene active on vague takeover speculation
Celgene (CELG) shares are active on speculation Bristol-Myers (BMY) may be interested in acquiring the company.
05:39 EDTCELGCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
April 23, 2015
17:45 EDTCELGCelgene announces fulfillment of approval requirements for POMALYST
Subscribe for More Information
10:30 EDTNLNKOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK PNK INFN WUBA MLNX CREE SKX CMG NOW FTNT
09:20 EDTCELGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
10:53 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
08:13 EDTTHLDThreshold: data suggest TH-4000 may overcome conventional EGFR-TKIs resistance
Subscribe for More Information
April 18, 2015
20:31 EDTTHLDThreshold Pharmaceuticals to hold analyst and investor day
Subscribe for More Information
April 15, 2015
17:08 EDTCELGCelgene announces phase 2 Apremilast data
Subscribe for More Information
April 14, 2015
13:32 EDTNLNKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
April 13, 2015
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
09:23 EDTNLNKNewLink Genetics April volatility elevated into data
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use